Prescient Therapeutics Ltd has released a press release.
Change to Exercise Price of Options
Filed with ASX ·
6ix hasn’t read this filing yet.
Prescient Therapeutics Limited on 6ix
Earlier from Prescient Therapeutics
- Canadian Patent Granted for PTX-200
- Entitlement Offer Results and Shortfall Notification
- March 2019 Appendix 4C - Quarterly
- Despatch of Entitlement Offer Documents
- Prospectus
Later from Prescient Therapeutics
- PTX Initiates Phase 1b Clinical Trial for PTX-100
- June 2019 Appendix 4C - Quarterly
- Appendix 4E and 2019 Annual Report
- September 2019 Appendix 4C - Quarterly
- Prescient Ausbiotech Ras Presentation
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics